Novo Nordisk, GoodRx and Ozempic
Digest more
GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to use GoodRx to self-pay for both Ozempic and Wegovy at the $499-per-month price at 70,000 U.S. retail pharmacies.
The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications. Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service,
GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click here to find out why GDRX is a Buy.
GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.
GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk.
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a household name, famous for helping people manage their weight, but this new indication could be a significant development. Here's why.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official website.